Long Term Outcomes of Kidney Donors with Fibromuscular Dysplasia
1Medicine, Houston Methodist Hospital, Houston, TX, 2Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX
Meeting: 2021 American Transplant Congress
Abstract number: 366
Keywords: Donation, Hypertension, Kidney
Topic: Clinical Science » Kidney » Kidney Living Donor: Long Term Outcomes
Session Information
Session Name: Live Kidney Donation
Session Type: Rapid Fire Oral Abstract
Date: Tuesday, June 8, 2021
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-6:05pm
Location: Virtual
*Purpose: Fibromuscular dysplasia (FMD) is not an infrequent finding during kidney donor evaluation. Current guidelines do not provide any recommendations regarding the use of kidneys from donors with FMD and there is a paucity of published data on the outcomes of donors with FMD. This is an important issue in donor selection and long term donor outcomes since FMD can be present in many vascular beds.
*Methods: We compared the development of hypertension, cardiovascular disease (CVD), proteinuria and reduced eGFR in 133 donors with FMD to 452 propensity score matched donors without FMD. The multivariable risks of these outcomes were determined by both logistic and Cox regression models. These donations took place between 1963 – 2007. The outcomes studied were ascertainable in 90-100% of the cohort.
*Results: Donors with FMD were older (51 vs. 39 years), more likely to be women (80 vs. 56%), and had a higher systolic blood pressure at donation (124.7 vs. 121.3 mmHg), p <0.05 for all. Donors with FMD were less likely to have the left kidney removed (31 vs. 72%), p=.01. After a mean follow-up of 15.5 ± 8.9 years, a similar proportion of donors with and without FMD developed hypertension (22.2 vs. 20.8%), proteinuria (20.6 vs. 15.3%) and CVD (13.3 vs. 12.9%). No donor with FMD developed an eGFR <30 ml/min/1.73 m2 or ESKD. The multivariable risk of these outcomes in donors with FMD was not elevated.
*Conclusions: Donors with FMD were older (51 vs. 39 years), more likely to be women (80 vs. 56%), and had a higher systolic blood pressure at donation (124.7 vs. 121.3 mmHg), p <0.05 for all. Donors with FMD were less likely to have the left kidney removed (31 vs. 72%), p=.01. After a mean follow-up of 15.5 ± 8.9 years, a similar proportion of donors with and without FMD developed hypertension (22.2 vs. 20.8%), proteinuria (20.6 vs. 15.3%) and CVD (13.3 vs. 12.9%). No donor with FMD developed an eGFR <30 ml/min/1.73 m2 or ESKD. The multivariable risk of these outcomes in donors with FMD was not elevated.
To cite this abstract in AMA style:
Adrogue HN, Evans A, Hebert SA, Adrogue HE, Nguyen DT, Murad D, Graviss EA. Long Term Outcomes of Kidney Donors with Fibromuscular Dysplasia [abstract]. Am J Transplant. 2021; 21 (suppl 3). https://atcmeetingabstracts.com/abstract/long-term-outcomes-of-kidney-donors-with-fibromuscular-dysplasia/. Accessed May 16, 2025.« Back to 2021 American Transplant Congress